 Tivantinib (ARQ197) is a selective, orally bioavailable, clinically advanced low-molecular weight and well-tolerated c-MET inhibitor, which is currently in Phase 3 clinical trials in non-small cell lung cancer patients.ARQ197 is a non-ATP competitive c-MET autophosphorylation inhibitor with a high selectivity for the unphosphorylated conformation of the kinase.Tivantinib cuts off the interactions between the key catalytic residues.